Senate report finds mifepristone makers fail safety oversight
Investigation led by Senator Bill Cassidy details concerns with online sales and prescriber auditing.
AI-assisted coverage comparison, editor-supervised · How this was made
Senate report finds mifepristone makers fail safety oversight
Photograph: Roll Call (embedded from source)
What this story says
- A Senate committee investigation found that manufacturers of the abortion pill mifepristone are not adequately upholding safety protocols, especially for online sales.
- The report, led by Senator Bill Cassidy, accuses companies of failing to audit prescribers and report adverse events.
- The Biden administration's expansion of mail-order access to mifepristone during the COVID-19 pandemic is identified as a contributing factor to increased online sales.
- The findings have prompted calls for legal and regulatory authorities to take action concerning the oversight of abortion pill manufacturers.
Who covered it
Percentages are shares of the 7 outlets carrying a published leaning rating. Coverage measured .
Trust
60/100
Craft
60/100
Hype
45/100
7 sources · methodology
Thin on the left so far
None of the 7 outlets with a published leaning rating that ran this story are rated left.
This story is still being watched, so it is a count and not yet a finding. Coverage keeps arriving for hours after an event, and a side that has published nothing this morning may publish by tonight. If it is still true when we stop checking, we will say so plainly.
An investigation by the Senate Health, Education, Labor and Pensions Committee has found that manufacturers of the abortion pill mifepristone are not adhering to required safety strategies, particularly when the drug is sold online. The report, led by Senator Bill Cassidy, identified issues with manufacturers not auditing prescribers or reporting non-fatal adverse events.
The investigation focused on three manufacturers: Danco Corporation, GenBioPro, and Evita Solutions. The report states that the expansion of mail-order access to mifepristone during the COVID-19 pandemic has contributed to a rise in online sales, creating potential for coercion and abuse. The committee's findings have led to calls for legal and regulatory bodies to address the oversight of these companies.
Disagreement on prescribing limits
The website Aid Access advertises prescribing mifepristone up to 14 weeks of pregnancy, which is beyond the 10-week limit set by the Food and Drug Administration. Roll Call reported that Senator Cassidy's report stated it was unclear who was providing the drug when ordered online and whether those parties were certified in the FDA's Risk Evaluation and Mitigation Strategy program. LifeNews.com reported that 81% of online abortion businesses send mifepristone far beyond the FDA's 10-week timeframe, citing research from the Charlotte Lozier Institute.
What the coverage left out
None of the centre or right-rated reports mentioned the specific figure of $1.2bn in profits that GenBioPro reportedly makes annually, as stated in the Washington Examiner's digest. The digests also did not include the specific details of the legal case Louisiana v. FDA, beyond mentioning it is set to resume on September 9.
Still developing. We have re-checked which outlets are covering this 4 times, most recently on 27 Aug 2026, 18:45, and will add the sides that appear.
How each side covered it
Our own reading of the reporting listed below, written from the outlets’ articles rather than quoted from them. The reasoning is set out on our methodology page.
Left
0 rated outlets
No outlet rated left has run this story so far. We are still checking, and will say plainly if that does not change.
Centre
3 rated outlets
- The centre-rated reports led on Senator Bill Cassidy's accusation that abortion pill manufacturers are failing to meet their legal obligations for safety compliance, especially with online sales through third parties. Both Roll Call and STAT News highlighted Cassidy's report, which calls for legal and regulatory authorities to take action. Roll Call noted that Cassidy, who is leaving Congress in January, accuses manufacturers of allowing third-party retailers to sell drugs without oversight and failing to report non-fatal adverse events. STAT News mentioned the report puts the high-profile issue on Heidi Overton as she faces confirmation as FDA commissioner.
Right
4 rated outlets
- Right-rated reports focused on the alleged dangers and lack of oversight associated with abortion pill manufacturers and online sales. LifeNews.com's headline stated that companies are selling 'Dangerous Abortion Pills to Kill Babies Up to Birth' and quoted Susan B. Anthony Pro-Life America calling for the Department of Justice to end mail-order mifepristone. The Washington Examiner reported that manufacturers are 'shirk[ing] oversight responsibility while making millions'. The Daily Signal reported that Cassidy 'Exposes Abortion Drug Companies Endangering Mothers'. LifeNews.com also cited incidents of alleged harm, including a Texas man facing charges after allegedly giving abortion drugs to a woman at approximately 14 weeks of pregnancy, and a case in North Carolina where a 31-week-old baby was born after the mother ordered drugs online.
Questions about this coverage
- How did the left and right cover Senate report finds mifepristone makers fail safety oversight?
- Of the 7 outlets on this story carrying a published leaning rating, 0% are rated left, 43% are rated centre, 57% are rated right. Those percentages are shares of the rated outlets, not of every outlet that ran it. The sections above set out what each side emphasised, in its own terms.
- Is Senate report finds mifepristone makers fail safety oversight left or right?
- Too few of the outlets on this story carry a published leaning rating to say. 7 of them do, and this site does not characterise a field under 12: at that size one newsroom filing moves the share by ten points. The percentages above are the count as it stands.
- Is the coverage of Senate report finds mifepristone makers fail safety oversight biased?
- Senate report finds mifepristone makers fail safety oversight is one event reported by 7 outlets, and this page does not rate the story as biased or unbiased. What it publishes is the spread: which outlets ran it, where named rating organisations place each of them on the spectrum, and what each side chose to lead with. A leaning rating describes an outlet's record over time, not this article, and the two should not be run together.
- Which side is not reporting Senate report finds mifepristone makers fail safety oversight?
- When we first saw this story, outlets rated left had barely covered it. Coverage accretes for hours after an event, so that is where to look rather than a verdict — the split above is the current count, and it is the one to read.
- Which outlets covered Senate report finds mifepristone makers fail safety oversight?
- 7 that we know of, every one of them listed further up this page with a link to its own report and to what we hold on the publisher. Nothing here is a summary of somebody else's summary: the outlets are named so the original reporting can be read.
- What are the main findings of the Senate committee investigation into mifepristone manufacturers?
- The Senate committee investigation found that manufacturers of the abortion pill mifepristone are not upholding required safety protocols, particularly for online sales. The report accuses companies of failing to audit prescribers and report non-fatal adverse events, calling for regulatory action.
- Which companies were investigated for their role in mifepristone manufacturing and distribution?
- The investigation by the Senate Health, Education, Labor and Pensions Committee focused on three mifepristone manufacturers: Danco Corporation, GenBioPro, and Evita Solutions. The report examined their adherence to safety regulations, especially concerning online sales.
- What role did the Biden administration's policies play in the investigation's findings?
- The report cites the Biden administration's expanded mail-order access to mifepristone during the COVID-19 pandemic as a factor contributing to increased online sales. This expansion is seen as having opened the door to potential coercion and abuse of women.
Read it at the source
7 outlets, grouped by the leaning a published rating gives them. Every headline links to the original; an underlined outlet name opens our profile of that publisher.
Left
0No outlet in this group ran the story.
Centre
3- Cassidy says abortion pill makers turn blind eye to safety (opens union-bulletin.com in a new tab)
union-bulletin.com — is union-bulletin.com biased? Our profile of this outlet
- Cassidy criticizes FDA oversight of abortion pill manufacturers in new report (opens STAT in a new tab)
- Cassidy says abortion pill makers turn blind eye to safety (opens Roll Call in a new tab)
Right
4- Study Shows Companies Selling Dangerous Abortion Pills to Kill Babies Up to Birth (opens LifeNews.com in a new tab)
LifeNews.com — is LifeNews.com biased? Our profile of this outlet
- Senate committee’s abortion drug probe reveals oversight concerns (opens Washington Times in a new tab)
Washington Times — is Washington Times biased? Our profile of this outlet
- Abortion pill makers shirk oversight responsibility while making millions, Senate GOP finds (opens Washington Examiner in a new tab)
Washington Examiner — is Washington Examiner biased? Our profile of this outlet
- SCOOP: Cassidy Exposes Abortion Drug Companies Endangering Mothers in New Report (opens The Daily Signal in a new tab)
The Daily Signal — is The Daily Signal biased? Our profile of this outlet
Not rated
0No outlet in this group ran the story.
How did this read?
About the coverage, not about the story. We do not ask whether you agree with what happened — we have no honest use for that answer.
